Roche Diabetes Care and Senseonics announce a distribution agreement for the Eversese (R) CGM system presented by the first long -term implantable glucose sensor.
Eversense is the first implantable sensor of continued glucose control (CGM) that measures glucose values for up to 90 days without changing the sensor every week or developing an additional reception device.
The system will allow people with diabetes to treat their disease more flexible, with confidence and discretion.
Roche (Six: RO, ROG; OTCQX: RHHby) today announced an exclusive distribution agreement with Senseonics Holding Inc. for the new Eversese (R) CGM system that will be marketed in Italy, Germany and the Netherlands.The system has been designed to continuously control glucose levels for up to 90 days, compared to 7 or up to 14 days of the non -implantable CGM system currently available in the market.
The sensor is implanted under the skin on the upper arm, and communicates with a rechargeable intelligent transmitter and that it can be removed that is carried in the upper arm.Glucose data and trends are available in the Eversese mobile application.
In addition, the smart transmitter establishes an alert when glucose levels are too low or too high.These characteristics provide people with diabetes with an important vision of real life about glucose levels and their trends during the day, in addition to action with action to manage their condition flexibly and discreetly.
According to the terms of the agreement, the CGM system with CE brand will be introduced into the first markets in Italy and Germany, and shortly after in the Netherlands.Both companies will make the Eversese system available for people with diabetes through clinics and medical practices with which the system has been formed.
"We are excited to be able to bring this advance within diabetes therapy to our clients. It is a device that fits perfectly and an addition to our Acu-Chek portfolio (R)," said Marcel Gmuender, a global manager ofRoche Diabetes Care.
"With the launch of our ACCU-Chek Insight CGM system at the end of this year, we are reinforcing our commitment to provide people with diabetes with broad access to innovation with two CGM solutions that will help meet the diverse needs of patientsand provide authentic relief. "